In @JAMANetworkOpen, we found that VA patients with #AFib who experience homelessness had a 21% ⬇️ odds of receiving stroke-preventing anticoagulation (blood thinners).
Previously, if you looked up "homeless & atrial fibrillation" in PubMed, only 5 results came up.
This included a 2003 @JAMAInternalMed study that saw that Ohio Medicaid enrollees had ⬇️ use of warfarin if they had homelessness or inadequate housing.
Second, our top-line finding was that even when controlling for sociodemographic (age, race, disability status), clinical comorbidities, and clinician/facility factors, patients experiencing homelessness were ⬇️ likely to receive any anticoagulant 💊.
On a positive note for #Pharmacoequity in the VA, we did find that if you are started on anticoagulant therapy, there was no difference in receipt of newer DOAC medications between those experiencing homelessness and those who were not.
In particular, how do we weigh clinical & social risk factors for patients when offering guideline-based therapies, not just for #AFib, but for the myriad conditions seen in patients w. homelessness?
I could go on but I'll end with gratitude to a 🌟🌟research team, including a med student and resident mentee and collaboration with @DrAudreyJones, whose @vahsrd Career Development Award is focused on improving mental health in homeless Veterans. 👇🏾
Also grateful to my mentors who provided their wisdom on the way to my 1st senior author original research pub... even to the point of coming off of the author list to help meet publication requirements. 🙏🏾
P.S. While homelessness & #AFib has been understudied, there has been important work in cardiovascular disease in general, including this study from @rkwadhera@kejoynt & team in JAMA IM.
This is a paper I reference regularly, a must-read if you haven't.
As part of a special issue on 💊 costs & access, we wrote a broad review on “Pursuing #Pharmacoequity - Determinants, Drivers, and Pathways to Progress.
We talk social & health policy, research, patient & prescriber factors. 👇🏾👇🏾
2/ Understanding the multilevel determinants that influence equitable access to medications (and trying to do so in <5000 words (!) was the goal of our review.
With so many factors out there, we know we only began to scratch the surface.
Led by future Dr. @rohankhaz, we dive into the challenges & opportunities in ensuring that patients and communities most affected by the pandemic can get the care they need.
2/ At risk of redundancy, we previously discussed the challenges in achieving #Pharmacoequity, including in the pandemic, noting, “…For example, treatment of patients with #COVID19 has revealed substantial inequities in access to life-saving treatments.”
3/ That observation was supported by national CDC data from earlier this year, as well as a recent national analysis of Medicare enrollees that found that Black patients had a 23% ⬇️ odds of receiving monoclonal antibodies when diagnosed with #COVID19.
A time for us to re-learn and re-discover our history.
A history beyond the chapter on Civil Rightsin our high school textbooks.
A history beyond the Emancipation Proclamation and Brown v. Board of Education.
So what are you reading this month?
2/ The ship grew larger & more terrifying w. each stroke of the paddle. The smells grew stronger, the sounds louder, crying & wailing from one quarter, low singing from another; the anarchic noise of children given an underbeat by hands drumming on wood.”
“Locked out of the greatest opportunity for wealth accumulation in history, African Americans who were able to afford homes found themselves consigned to communities where their investments were affected by the FHA.”
One of the points we made in our article last month (👇🏾) is that #Pharmacoequity extends beyond prescription drug access to the entire therapeutic cascade. A couple of interesting papers led by @ashwin_nathan & @ACFanaroff on TAVRs and #HealthEquity.
3/3 A month later, the team showed in @JAMACardio that zip codes with ⬆️ rates of Black & Hispanic patients and those with more socioeconomic disadvantages had ⬇️ rates of TAVR, adjusting for age and clinical conditions.
2/ Ensuring that all individuals, regardless of race & ethnicity, socioeconomic status, or availability of resources, have access to the highest quality medications required to manage their health needs is paramount. This is what we call #Pharmacoequity.
3/ The #COVID19 pandemic has brought health equity to the forefront, especially in how we ensure access to novel therapies, from antivirals like #remdesivir and #molnupiravir to the Covid vaccine...
But inequities in access to novel drugs are much more than a Covid problem. 👇🏾
2/ The pandemic has taught us so much about our health system, but it has especially shone a bright light on the social determinants as key drivers of #HealthEquity. Our review focused on:
🔸 race/ethnicity
🔸 finances
🔸 rurality/neighborhood
🔸 health literacy
🔸 social network
3/ The social construct of race has been one of the most well-studied determinants of #AFib incidence, treatment (including our work in anticoagulation disparities), and outcomes. Here we discuss why such inequities exist across the AFib care continuum.